Factors influencing clinical efficacy and outcomes of adult primary immune thrombocytopenia
10.3760/cma.j.issn.1671-7368.2018.10.010
- VernacularTitle:成人原发免疫性血小板减少症161例疗效及预后的影响因素分析
- Author:
Yu CHEN
1
;
Meifang WANG
;
Jianfang CHEN
;
Yaofang ZHANG
;
Gang WANG
;
Zefeng AN
;
Shuting CHANG
;
Linhua YANG
Author Information
1. 山西医科大学第二医院血液科
- Keywords:
Thrombocytopenia;
Treatment outcome;
Prognosis
- From:
Chinese Journal of General Practitioners
2018;17(10):794-797
- CountryChina
- Language:Chinese
-
Abstract:
Objective To examine the influencing factors related to clinical efficacy and outcomes of adult primary immune thrombocytopenia (ITP).Methods The clinical data of 161 cases of ITP admitted in the Second Hospital of Shanxi Medical University from June 2013 to March 2017 were collected.The influencing factors related to clinical efficacy and prognosis of adult ITP patients were analyzed.Results There were 60 males and 101 females with a M/F ratio of 0.59∶1 and a median age of 45 years (18-84 years).There were 109 newly diagnosed ITP cases,14 persistent ITP cases and 38 chronic ITP cases in this series.Seventy nine patients received intravenous immunoglobulin g (IVIg) treatment and 82 patients received high dose-dexamethasone treatment.There were no significant differences in clinical efficacy [91.13％(72/79) vs.87.80％(72/82),x2=0.181,P=0.914] and relapse rate [36.11％(26/72) vs.30.55％(22/72),x2=0.189,P=0.910] between IVIg and high dose-dexamethosone groups.Multivariate regression analysis showed that bleeding score ≥2 was the independent risk factor for the lower clinical efficacy (RR=1.415,95％CI:1.008-1.986,P＜0.05).Patients were followed up for a median of 9.0 months (0.5-55.0 months),48 patients relapsed with a relapse rate of 33.33％ and a median relapse time of 1.8 months (0.5-24.0 months).Conclusions IVIg and high dose-dexamethasone have the similar clinical efficacy and relapse rate for treatment of adult ITP.The patients with the bleeding score ≥2 are more likely to get lower remission rate.
